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Elevated plasma triglyceride (TG) levels are an indepen-
dent risk factor for CVD and all-cause mortality (1). The 
concentration of plasma TG levels reflects a balance be-
tween de novo synthesis in the liver (VLDLs), intestinal ab-
sorption of dietary lipids (chylomicrons), lipolysis in the 
peripheral circulation, and hepatic clearance. TG-rich li-
poproteins (TRLs) carry TGs in the blood and are rapidly 
hydrolyzed by LPL, thereby releasing free FAs for energy 
production or storage in the surrounding tissues (2–4). 
The remnant TRLs are subsequently rapidly cleared in the 
liver by the interaction of apolipoproteins on TRLs with 
the three main hepatic receptors, heparan sulfate proteo-
glycan syndecan-1 (SDC1), LDL receptor (LDLR), and 
LDLR-related protein 1 (LRP1) (5).
TRLs carry several apolipoproteins, including apoB, 
apoE, apoAV, and apoC-III. ApoB and apoE serve as li-
gands for LDLR and LRP1, promoting hepatic TLR clear-
ance (6–10). In contrast, hepatic SDC1 recognizes apoE 
and apoAV, dependent on the interaction of these apolipo-
proteins with the heparan sulfate side chains on SDC1 (9). 
Human apoE is a 299 amino acid polymorphic glycoprotein 
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synthesized and secreted primarily by liver, brain, skin, 
and macrophages (11). In humans, three isoforms, apoE4 
(A112/A158), apoE3 (C112/A158), and apoE2 (C112/
C158), differ by single amino acid substitutions at two key 
nonsynonymous sites. ApoE3 and apoE4 can bind to LDLR 
and LRP1, whereas apoE2 does not. ApoC-III is an 8.8 kDa 
glycoprotein present on all lipoprotein classes and one of 
the key modulators of TG metabolism (12). Transgenic ex-
pression of Apoc3 results in hypertriglyceridemia in mice 
(13), whereas gene targeted deletion of Apoc3 decreases 
TG levels (14). The importance of apoC-III in humans was 
established by the findings that inactivating mutations were 
shown to correlate with lower plasma TGs (15) and to pro-
tect against CVD (16–18). Depressing APOC-III expression 
using an antisense oligonucleotide (ASO), volanesorsen, 
also reduces plasma TGs in mildly hypertriglyceridemic 
patients (5, 19–21). In a recent clinical study, treatment 
of massively hypertriglyceridemic LPL-deficient patients 
(<5% LPL activity) with volanesorsen resulted in profound 
lowering of plasma TG levels as well, consistent with the 
idea that apoC-III also modulates plasma TG levels in a 
non-LPL-dependent manner, likely via LDLR/LRP1-mediated 
clearance (5, 19).
It remains unclear exactly how apoC-III blocks LRP1- 
and LDLR-mediated TRL clearance. Direct inhibition of 
apoC-III on apoE-mediated TRL binding to LDLR and 
LRP1 as well as the competition between apoE and apoC-
III for space on TRLs have been proposed as mechanisms 
(13, 14, 22–24). However, intercrossing Apoc3/ mice with 
Apoe/ mice resulted in a marked reduction in VLDL TG, 
indicating that apoC-III deficiency exerts its lipid-lowering 
effect independently of apoE (25). At the time these studies 
were underway, the participation of SDC1-mediated clear-
ance was not fully appreciated.
Thus, we set out to analyze the impact of suppressing 
apoC-III expression on TRL clearance and lipid levels in 
the absence of apoE and SDC1-mediated TRL clearance. 
We probed this question in mice lacking functional SDC1 
by liver-specific targeted inactivation of Ndst1, an enzyme 
involved in formation of the heparan sulfate chains com-
pounded by apoE-inactivation (Apoe/Ndst1f/fAlb-Cre+). 
Hence, both apoE-mediated TRL clearance through 
LDLR/LRP1- and SDC1-mediated TRL clearance were 
abolished. Based on our previous studies showing that 
apoC-III targeting lowered TG levels independent of LPL 
expression, we anticipated to find no or only a minor effect 
of targeting apoC-III on plasma TG levels due to the lack of 
TRL clearance (5, 19). However, we observed that adminis-
tration of apoC-III ASO to Apoe/Ndst1f/fAlb-Cre+ mice 
dramatically reduced TG levels, independently of TRL 
clearance or hepatic VLDL production. Plasma and hepa-
rin-releasable LPL levels were unaffected in this model as 
well. Further analysis showed that apoC-III lowering in the 
absence of apoE expression elevated LPL activity and TG 
hydrolysis in white adipose tissue (WAT). We also show that 
the administration of APOC-III ASO to patients significantly 
reduced plasma TGs independently of the APOE isoform, 
even in APOE2 homozygous patients, which is in line with 
the observed apoC-III ASO-mediated TG-lowering in mice.
METHODS
Mice
Apoe/,Alb-Cre+ and Ldlr/ mice were purchased from the 
Jackson Laboratory. Ndst1f/fAlb-Cre+, Apoe/Ndst1f/fAlb-Cre+, and 
Ldlr/Ndst1f/fAlb-Cre+ mice were generated and genotyped as de-
scribed (26, 27). All animals were fully backcrossed onto the 
C57Bl/6 background. All animals were housed and bred in vivaria 
approved by the Association for Assessment and Accreditation of 
Laboratory Animal Care located in the School of Medicine, Uni-
versity of California, San Diego, following standards and proce-
dures approved by the University of California, San Diego 
Institutional Animal Care and Use Committee. Mice were weaned 
at 4 weeks, maintained on a 12 h light cycle, and fed ad libitum 
with water and standard rodent chow (PicoLab® Rodent Diet 20 
5053) or a Western diet (WD) (TD.88137; Envigo Teklad). Mice 
received ION 440726 (murine apoC-III ASO) or ION 141923 
(murine control ASO) at 50 mg/kg/week (supplemental Table 
S1) via intraperitoneal injections.
Lipid analysis
Lipid levels were analyzed in plasma and liver samples. Blood 
was drawn via the tail vein from mice fasted for 5 h. Total plasma 
cholesterol and TG levels were determined using commercially 
available kits (Sekisui Diagnostics). Cholesterol in VLDL fractions 
was measured with the Amplex Red cholesterol assay kit (Thermo 
Fisher Scientific). Plasma NEFA and 3-hydroxybutyrate levels 
were determined using enzymatic kits (Wako Chemicals). Liver 
samples were homogenized using a hypotonic extraction buffer 
[250 mM sucrose, 5 mM Tris, 1 mM EDTA, and proteinase inhibi-
tor (cOmplete; Sigma)] and total cholesterol and TG were deter-
mined in the supernatant after centrifugation as described above.
RNA analysis
Total RNA was isolated with Trizol from homogenized tissue and 
cells and purified using RNeasy columns and RNase-free DNase di-
gestion according to the manufacturer’s instructions (Qiagen). The 
quality and quantity of the total RNA was monitored and measured 
via NanoDrop (NanoDrop Technologies, Inc., Wilmington, DE) fol-
lowing the manufacturer’s instructions. For quantitative PCR analy-
sis, 1 l of cDNA was used for real-time PCR with gene-specific 
primers (supplemental Table S2) and Tbp as a housekeeping gene 
on a Bio-Rad CFX96 real-time PCR system (Bio-Rad).
Fast-performance LC
Plasma was pooled from several mice (100 l per mouse, n = 3–5 
mice per genotype) and separated by gel filtration fast-performance 
(FP)LC using a GE Superose 6 10/300 GL column in 0.15 M 
sodium chloride containing 0.01 M disodium hydrogen phos-
phate and 0.2 mM EDTA (pH 7.4). Fractions (0.5 ml) were col-
lected (0.5 ml/min) and total cholesterol and TG levels were 
determined enzymatically as described above.
Ultracentrifugation
Lipoprotein fractions from pooled plasma samples were sepa-
rated by buoyant density ultracentrifugation according to estab-
lished methods (28). Briefly, 100 l of pooled plasma was loaded 
into micro-ultracentrifuge tubes (Beckman). The samples were 
centrifuged for 12 h in a 42.2 Ti rotor at 175,000 g at 18°C (Beck-
man). The top 50 l fraction containing VLDL and chylomicron 
remnants ( < 1.006 g/ml) was collected and used for analysis.
Western blot analysis
Liver (25 g), brown adipose tissue (BAT) (20 g), and gonadal 
WAT (gWAT) (20 g) homogenized in PBS, 2 mg/ml BSA, and 
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5 U/ml heparin and isolated TRLs (5 g) were analyzed by SDS-
PAGE on 4–12% Bis-Tris gradient gels (NuPage; Invitrogen) with an 
equal amount of protein loading. Proteins were visualized by silver 
staining (Pierce) or after transfer to Immobilon-FL PVDF mem-
brane (Millipore). Membranes were blocked with Odyssey blocking 
buffer (LI-COR Biosciences) for 30 min and incubated overnight at 
4°C with respective antibodies. Goat, mouse, and rabbit antibodies 
were incubated with secondary Odyssey IR dye antibodies (1:14,000) 
and visualized with an Odyssey IR imaging system (LI-COR Biosci-
ences). Western blot primary antibodies included: mouse anti-
mouse -actin (Sigma, A2228; 1:5,000), rabbit anti-mouse apoB 
(Abcam, ab20737; 1:1,000), rabbit anti-mouse apoC-III (IONIS 
Pharmaceuticals; 1:2,000) (29), rabbit anti-mouse apoE (Meridian 
Life Sciences, K23100R; 1:1,000), and goat anti-mouse LPL (pro-
vided by S. Young, University of California, Los Angeles; 10 g/ml).
Postprandial clearance studies
After 5 h fasting, mice were given a 250 l bolus of corn oil 
(Sigma-Aldrich) by oral gavage. At the indicated time points, mice 
were bled via the tail vein. TG and cholesterol levels were mea-
sured as described above.
Hepatic VLDL-TG secretion
Mice were fasted for 5 h prior to a tail vein injection of Tyloxa-
pol (10% solution in PBS; Sigma) at a dose of 0.5 mg/g body 
weight. Plasma was collected by tail bleeding at time points 1, 15, 
30, 60, and 120 min after injection. Plasma TG levels were mea-
sured as described above.
Lipid absorption
Intestinal lipid absorption was analyzed in mice treated with a 
control ASO or apoC-III ASO for 4 weeks. After 5 h fasting, the 
mice were injected via the tail vein with Tyloxapol (10% solution 
in PBS; Sigma) at a dose of 0.5 mg/g body weight followed by a 
250 l bolus of corn oil (Sigma-Aldrich) by oral gavage. Blood was 
drawn via the tail vein at the indicated time points and plasma TG 
levels were measured as described above.
Retinyl ester excursion
Clearance of chylomicrons derived from dietary TG was mea-
sured by vitamin A excursion essentially as described (5). Briefly, 
250 l of corn oil containing 5 Ci of [11,12-3H]retinol (Perkin 
Elmer; 44 Ci/mmol) in ethanol were administered by oral gavage 
to mice fasted from 4:00 AM to 9:00 AM. Blood was obtained every 
2 h via the tail vein at the indicated time points and [3H] counts 
in plasma were measured by liquid scintillation counting.
Clearance of [3H]TRLs in vivo
Mice were treated for 4 weeks with a control ASO or apoC-III 
ASO. Mice were fasted for 5 h and subjected to oral gavage (250 
l/mouse) with 5 Ci [11,12-3H]retinol in corn oil (Sigma- 
Aldrich). Blood was collected 3 h post-gavage by cardiac puncture 
post-euthanasia using isoflurane. [3H]TRLs were isolated by buoy-
ant density ultracentrifugation as described above. In parallel, an 
acceptor group of mice were treated with apoC-III ASO for 
4 weeks, fasted for 5 h, and then injected intravenously with freshly 
purified [3H]TRLs, either enriched or depleted in apoC-III 
(20,000 cpm per mouse). Serial tail vein blood samples were taken 
at the indicated times. Radioactivity in serial plasma samples was 
determined by liquid scintillation counting and expressed relative 
to the number of counts in the circulation 1 min after injection.
Liposyn [3H]triolein tissue uptake
Preparation of liposyn solution (Sigma-Aldrich) containing 
5 Ci [3H]triolein was performed as described (5). Briefly, 10 l of 
[3H]triolein were slowly evaporated to dryness under N2 in a glass 
vial. Five hundred microliters of 5% Liposyn solution were added 
and sonicated three times for 20 s at 40 W to incorporate [3H]tri-
olein into the emulsion (on ice). After centrifugation (14,000 g 
for 15 min at 4°C), 100 l of [3H]triolein-labeled liposyn particles 
were injected intravenously into mice treated for 4 weeks with a 
control ASO or apoC-III ASO and fasted for 5 h. Five minutes 
after injection, blood was collected, the mice were perfused with 
10 ml PBS via the left ventricle, and the indicated tissues were 
harvested. The tissues were homogenized in 1 ml SOLVABLE 
(Perkin Elmer) at 50°C until digested. [3H]triolein tissue uptake 
and remaining [3H] counts in plasma were measured by liquid 
scintillation counting, and protein was determined by BCA assay 
(Thermo Fisher Scientific).
[3H]FA uptake in vivo
The uptake of radiolabeled FA into various tissues was deter-
mined in mice on control ASO or apoC-III ASO. Fasted mice (5 h) 
were injected retro-orbitally with 1 Ci of [3H]palmitic acid com-
plexed with FA-free BSA (1:1 molar ratio). The uptake of FA 
into tissues was measured by scintillation counting as described 
above.
Binding and uptake of [3H]TRLs in vitro
ApoC-III-depleted and apoC-III-enriched [3H]TRL particles 
were isolated from control ASO- and apoC-III ASO-treated 
Apoe/Ndst1f/fAlb-Cre+ mice, respectively, as described above. Next, 
primary hepatocytes were isolated from control ASO- or apoC-III 
ASO-treated Apoe/Ndst1f/fAlb-Cre+ mice by perfusion of the liver 
with EDTA to dissociate the cells, followed by Percoll centrifuga-
tion as described (30). Hepatocytes were cultured in DMEM con-
taining 10% FBS, 100 units/ml penicillin, and 0.1 mg/ml 
streptomycin for 48 h prior to in vitro experiments. Uptake experi-
ments were performed in hepatocytes seeded into collagen-coated 
6-well plates (Nalgene Nunc International, Pennfield, NY) at 
500,000 cells/well. Sixteen hours prior to the experiment, hepato-
cytes were cultivated in DMEM containing 10% lipoprotein-
deficient serum. On the next day, the cells were washed with PBS 
and purified [3H]TRLs were added in a concentration of 10, 20, 
50, and 100 g/ml in DMEM. After a 4 h incubation at 37°C, the 
cells were washed four times with PBS. Hepatocytes were solubi-
lized in 1 M NaOH containing 1 g/l SDS. Finally, total radioactivity 
and total cell protein content of the lysate were determined. All 
uptake data were obtained as triplicates. To analyze the impact of 
apoE on binding and uptake, hepatocytes were reconstituted with 
apoE as described previously (9). In brief, purified apoE-deficient 
[3H]TRL particles isolated from Apoe/Ndst1f/fAlb-Cre+ mice (100 
g) were incubated with recombinant human APOE2 or -E3 (50 
g; PeproTech, Inc.), respectively, at 37°C for 1 h in PBS. ApoE- 
reconstituted [3H]TRLs were floated by ultracentrifugation and 
the top fraction ( < 1.006 g/ml) was collected. Incorporation of 
recombinant human apoE was verified via SDS-PAGE with silver 
staining. Hepatocytes were cultured 48 h prior to the experiments, 
as described above, and reconstituted [3H]TRLs were added at the 
indicated concentrations. Binding studies were performed in a 
similar manner. Hepatocytes were incubated for 1 h on ice with 
ice-cold medium containing [3H]TRLs with or without lipoprotein- 
deficient serum, and bound [3H]TRLs were analyzed as described 
previously (9).
[14C]FA uptake in vitro
Hepatocytes enriched or depleted in apoC-III were isolated 
from control ASO- and apoC-III ASO-treated Apoe/Ndst1f/fAlb-
Cre+ mice, respectively, and cultured as described above. After 
washing with PBS, hepatocytes were incubated with 0.5 Ci [14C]
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oleic acid complexed with FA-free BSA (1:1 molar ratio) at 37°C. 
At the indicated time points, the cells were lysed and uptake of 
radiolabeled FA was determined as described above.
Heparin push
Release of LPL into circulation was induced by heparin injec-
tions. Mice were fasted for 5 h and 50 U of heparin were injected 
intravenously. For postprandial studies, mice were given an oral 
corn oil gavage (250 l) after 5 h fasting. Three hours later, 50 U 
of heparin were injected intravenously; 40 l of blood was drawn 
before and 10 min after the injections and immediately chilled on 
ice and centrifuged (2,000 g for 5 min) at 4°C to prevent ongoing 
lipolysis. Fasted and postprandial TG levels were measured as de-
scribed above.
Lipase activity assays
Lipoprotein and hepatic lipase (HL) were determined in 
Apoe/Ndst1f/fAlb-Cre+ mice administered control ASO or apoC-
III ASO for 4 weeks as described previously (31). Briefly, 20 l of 
post-heparin plasma was incubated with a 100 l [3H]triolein- 
radiolabeled emulsion for 30 min at 37°C (5). The generated FAs 
were extracted and the radioactivity was determined by liquid 
scintillation counting. The contribution of HL was determined by 
including 1 M NaCl in the assay, and the values were subtracted 
from the total lipase activity to estimate the activity attributed to 
LPL. To measure lipase activities in tissues, samples were minced 
and reconstituted in 0.6 ml PBS containing 2 mg/ml BSA and 
5 U/ml heparin. Protein concentration was measured and cor-
rected for the addition of BSA. The aim of the LPL assay in tissues 
was to estimate the fraction of LPL that could be released by hepa-
rin. Minced tissues were incubated for 1 h in a 37°C shaker and 
subsequently centrifuged at 1,000 g for 15 min. One hundred mi-
croliters of the supernatant were used for the lipase assay in com-
bination with 100 l of [3H]triolein-radiolabeled emulsion. The 
LPL activity measurements were normalized for the amount of 
protein.
Clinical study
Study design and oversight of the phase 2 randomized double-
blind placebo-controlled dose-ranging study designed to evaluate 
the pharmacodynamic effects of ISIS 304801 on fasting APOC-III 
and TG levels in adult patients with severe or uncontrolled hyper-
triglyceridemia was described previously (21). Patients assigned to 
the ISIS 304801 monotherapy cohort were randomly assigned in 
a 1:1:1 ratio to receive a weekly dose of 100, 200, or 300 mg; the 
patients in these dose groups were then randomly assigned in a 
3:1 ratio to receive active agent or placebo. Patients assigned to 
the ISIS 304801-fibrate cohort were randomly assigned in a 1:1 
ratio to receive a dose of 200 or 300 mg; patients in these dose 
groups were then randomly assigned in a 2:1 ratio to receive active 
agent or placebo. The study drug was administered as a single 
subcutaneous injection once a week for 13 weeks as monotherapy 
or as an add-on to fibrate treatment. The primary outcome was 
the percentage change in fasting total APOC3 levels from base-
line (level at day 8) to the end of treatment (mean of the levels 
at day 85 and day 92). Lipid measurements and APOE genotypes 
were assessed as described (21).
RNA sequencing
RNA was isolated as described above. RNA sequencing was per-
formed at the Institute for Genomic Medicine at University of 
California, San Diego on an Illumina HiSeq 4000 using single-end 
read sequencing and a ribo-depleted RNA stranded library. The 
spliced read aligner STAR (32) was used to align sequencing 
reads to the mouse GRCm38 genome. Gene-level read counts 
were obtained with feature Counts (33) and Ensembl gene anno-
tation. DESeq2 (34) was used to calculate differential gene ex-
pression based on uniquely aligned reads, and P-values were 
adjusted for multiple hypothesis testing with the Benjamini-
Hochberg method.
[13C] tracing experiments
U-[13C16]palmitic acid tracer was purchased from Cambridge 
Isotopes Inc. Stable isotope labeling of intracellular metabolites 
was performed in primary hepatocytes isolated from Apoe/Ndst1f/f 
Alb-Cre+ mice on control ASO or apoC-III ASO as described above. 
Tracing experiments were performed in hepatocytes seeded into 
collagen-coated 12-well plates (Nalgene Nunc International) at 
250,000 cells/well. For analysis of FA incorporation into the TCA 
cycle, hepatocytes were incubated for 1 h or 4 h with serum-free 
DMEM supplemented with 20 M U-[13C16]palmitic acid conju-
gated in a 3:1 ratio with BSA. FA biosynthesis and TCA cycle incor-
poration were analyzed by GC/MS analysis.
GC/MS analysis
Polar metabolites and FAs were extracted using methanol/ 
water/chloroform and analyzed as previously described (35). 
Briefly, hepatocytes were washed with saline (0.9%) after incuba-
tion with U-[13C16]palmitic acid. Ice-cold methanol and water 
containing norvaline as internal standard were added to collect 
the cells. Next, chloroform containing U-[2H31]palmitate stan-
dard was added, and the aqueous/organic layers were separated 
by centrifugation. Polar metabolites were derivatized in 20 l of 
2% (w/v) methoxyamine hydrochloride (Thermo Scientific) in 
pyridine and incubated at 37°C for 60–90 min. Samples were 
then silylated with 30 l of N-tert-butyldimethylsilyl-N-methyltri-
fluoroacetamide with 1% tert-butyldimethylchlorosilane (Regis 
Technologies) at 37°C for 30–45 min. Samples were centrifuged 
at 21,000 g for 5 min and the supernatant was transferred to GC 
sample vials for analysis. Derivatized polar metabolites were ana-
lyzed by GC/MS using a DB-35MS column (30 m × 0.25 mm in-
ner diameter × 0.25 m; Agilent J&W Scientific) installed in an 
Agilent 7890B gas chromatograph interfaced with an Agilent 
5977A mass spectrometer. Extracted nonpolar metabolites were 
evaporated, saponified, and esterified to form FA methyl esters 
(FAMEs) through addition of 500 l of 2% (w/v) H2SO4 in meth-
anol and incubation at 50°C for 90–120 min. FAMEs were ex-
tracted after addition of 100 l of saturated NaCl solution with 
two 500 l hexane washes and evaporated to dryness before re-
suspension in 50–100 l of hexane and transfer to glass GC vials 
for analysis. Derivatized FAMEs were analyzed by GC/MS using a 
Select FAME column (100 m × 0.25 mm inner diameter × 0.25 m; 
Agilent J&W Scientific) installed in an Agilent 7890A gas chro-
matograph interfaced with an Agilent 5975C mass spectrometer.
Lipoprotein subclasses
Concentrations of plasma lipoprotein subclasses were mea-
sured by specific particle-size intervals from HDL to VLDL using 
ion mobility (36). Particle concentrations (in nanomoles per 
liter) were measured for lipoprotein subclasses defined by the 
following size intervals: HDL3/2a (76.5–105.0 Å), HDL2b (105.0–
145.0 Å), midzone between HDL and LDL (145.0–180.0 Å), LDL4c 
(180.0–190.0 Å), LDL4b (190.0–199.0 Å), LDL4a (199.0–204.9 Å), 
LDL3b (204.9–208.2 Å), LDL3a (208.2–214.1 Å), LDL2b (214.1–
220.0 Å), LDL2a (222.0–224.6 Å), LDL1 (224.6–233.3 Å), IDL2 
(233.3–250.0 Å), IDL1 (250.0–296.0 Å), small VLDL (296.0–335.0 Å), 
intermediate VLDL (335.0–424.0 Å), and large VLDL (424.0–
547.0 Å). LDL peak diameter was determined by ion mobility as 
described previously (37).
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Statistics
Statistical analyses were performed using Prism software (ver-
sion 5; GraphPad Software). Data were analyzed by Wilcoxon 
rank-sum test, two-tailed Student’s t-test, or two-way ANOVA de-
pending on normality of the data and presented as mean ± SEM. 
P-values less than 0.05 were considered significant.
RESULTS
ApoC-III ASO reduces plasma TG levels in Apoe/Ndst1f/f 
Alb-Cre+ mice
To determine the impact of apoE on apoC-III-mediated 
inhibition of LDLR/LRP1-mediated TRL clearance, we ad-
ministered an ASO targeting Apoc3 (50 mg/kg/week) to 
chow-fed mice deficient in Apoe and Ndst1 (Apoe/Ndst1f/f 
Alb-Cre+). By using Apoe-deficient mice compounded with 
hepatic Ndst1 inactivation, we established a model to evalu-
ate the role of apoE, a shared ligand between LDLR and 
LRP1, on apoC-III-mediated inhibition of TRL clearance 
without interference of SDC1-mediated TRL clearance. 
Hepatic Apoc3 mRNA levels decreased by 88.0 ± 7.5% in 
Apoe/Ndst1f/fAlb-Cre+ mice treated with apoC-III ASO 
compared with control ASO. After 2, 4, and 8 weeks of ASO 
treatment, plasma TG levels were significantly reduced by 
34.1 ± 13.3% (P < 0.0001), 36.5 ± 7.1% (P = 0.0008), and 
42.4 ± 14.8% (P < 0.0001), respectively, compared with 
mice treated with control ASO (Fig. 1A, B). Size-exclusion 
chromatography analysis of plasma after 4 weeks of ASO 
treatment revealed that the reduction in TGs was associ-
ated with a decrease in chylomicron remnant and VLDL 
levels (Fig. 1C). ApoC-III ASO treatment had a minimal 
effect on plasma cholesterol levels (Fig. 1D–F) despite a 
significantly reduced apoC-III content on TRLs isolated 
from Apoe/Ndst1f/fAlb-Cre+ mice (Fig. 1G). Liver TG levels 
were unaffected, while hepatic cholesterol content was 
modestly increased by 20.1 ± 28.4% (P = 0.03) in the apoC-
III ASO treatment group (Fig. 1H, I). Similar results 
were observed in Apoe/ mice, although less pronounced, 
which was likely due to compensation by apoC-III-indepen-
dent TRL clearance mediated by SDC1 (supplemental Fig. 
S1). Hence, we used Apoe/Ndst1f/fAlb-Cre+ mice in subse-
quent experiments.
We next analyzed the impact of apoC-III ASO adminis-
tration on Apoe/Ndst1f/fAlb-Cre+ mice fed a WD. In gen-
eral, the WD increased cholesterol levels, as expected, and 
decreased TG levels, as observed in previous studies using 
Apoe/ mice (30). Interestingly, in response to apoC-III 
ASO treatment, no significant differences in TG and cho-
lesterol levels were observed at 2 and 4 weeks; though 
again, a minimal decrease in cholesterol occurred at 8 
weeks (Fig. 2D–F) of apoC-III ASO treatment compared 
with the control ASO group (Fig. 2A–F). Again, apoC-III 
ASO administration markedly reduced Apoc3 expression by 
92.0 ± 1.9% and apoC-III content on TRLs isolated from 
Apoe/Ndst1f/fAlb-Cre+ mice on the WD (Fig. 2G). Hepatic 
TG and cholesterol levels were elevated on the WD com-
pared with chow diet but not different between treatment 
groups (Fig. 2H, I). No differences in bodyweight gain 
were observed during the treatment period on both chow 
and WD diet as a result of apoC-III knockdown (Figs. 1J, 
2J). Taken together, the results suggest that apoC-III lower-
ing by ASOs can improve plasma TG levels in the absence 
of Apoe expression.
Postprandial TG response and VLDL production are 
unaltered by apoC-III ASO treatment
To investigate whether suppression of apoC-III improves 
clearance of dietary TGs independently of apoE, we per-
formed a fat tolerance test (Fig. 3A). Fasted chow-fed 
Apoe/Ndst1f/fAlb-Cre+ mice were given corn oil by oral ga-
vage and plasma TG levels were analyzed at the indicated 
time points. ApoC-III ASO-treated mice had lower basal and 
postprandial TG levels (Fig. 3A). Similar data were gener-
ated in WD-fed Apoe/Ndst1f/fAlb-Cre+ mice (supplemental 
Fig. S2). The reduction in pre- and post-prandial plasma TG 
levels induced by apoC-III ASO could not be explained by 
changes in intrahepatic VLDL secretion of TGs (Fig. 3B) or 
intestinal lipid absorption (Fig. 3C) as measured by accu-
mulating plasma TG levels after intravenous injection of the 
lipase inhibitor, Tyloxapol, under fasting and feeding (corn 
oil gavage) conditions, respectively.
We previously showed that apoC-III ASO significantly im-
proved hepatic [3H]retinol-TRL clearance in Ndst1f/fAlb-Cre+ 
mice (5). To evaluate whether apoC-III modulates hepatic 
TRL clearance in the absence of apoE, Apoe/Ndst1f/fAlb-
Cre+ mice treated with control or apoC-III ASO were given an 
oral bolus of corn oil containing [3H]retinol, which is con-
verted to retinol esters and packaged into chylomicrons. Re-
markably, [3H]retinol excursion was similar between apoC-III 
ASO- and control ASO-treated Apoe/Ndst1f/fAlb-Cre+ mice 
(Fig. 3D), suggesting that apoE is crucial for apoC-III-mediated 
inhibition of hepatic TRL clearance. Additional support for 
this conclusion was obtained by measuring the clearance rate 
of apoC-III-rich and apoC-III-poor [3H]TRL particles in vivo. 
Apoe/Ndst1f/fAlb-Cre+ mice treated with apoC-III ASO or 
control ASO were given [3H]retinol-radiolabeled corn oil by 
gavage to generate [3H]retinol-labeled apoC-III-depleted 
and apoC-III-enriched [3H]TRLs, respectively (Fig. 3E). 
Equal counts of apoC-III-enriched or apoC-III-depleted mu-
rine [3H]TRLs (20,000 cpm per mouse) were injected into 
recipient Apoe/Ndst1f/fAlb-Cre+ mice. All recipient mice had 
been pretreated with apoC-III ASO for 4 weeks to minimize 
the association of endogenously produced apoC-III with the 
injected [3H]TRLs (Fig. 3E). Unlike previous results in 
Ndst1f/fAlb-Cre+ mice (5), the clearance rates of apoC-III-
enriched or apoC-III-depleted [3H]TRLs injected into 
Apoe/Ndst1f/fAlb-Cre+ mice were identical (Fig. 3F). [3H]TRL 
tissue distribution in Apoe/Ndst1f/fAlb-Cre+ mice was unaf-
fected by the presence or absence of apoC-III on [3H]TRLs 
(data not shown). Together, the findings support that lower-
ing of plasma TG levels by apoC-III ASOs in the absence of 
apoE expression is not a result of improved hepatic TRL 
clearance or altered VLDL and chylomicron production.
ApoE is required for apoC-III-mediated inhibition of 
hepatic TRL clearance
We further analyzed the importance of apoE in 
apoC-III-mediated hindrance of hepatic TRL clearance. 
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[3H]retinol-radiolabeled apoC-III-depleted and apoC-III-
enriched TRLs (Fig. 3E) were evaluated for their binding 
and uptake capacity by primary hepatocytes isolated from 
apoC-III ASO-treated Apoe/Ndst1f/fAlb-Cre+ mice. Binding 
(4°C) and uptake (37°C) of apoE-deficient [3H]retinol- 
labeled TRLs were not affected by the presence or absence 
of apoC-III (Fig. 4A). In contrast, reconstitution of the 
same [3H]retinol-labeled apoE-deficient TRLs with apoE 
resulted in a significant reduction in clearance of apoC-III-
enriched TRLs compared with apoC-III-depleted TRLs 
(Fig. 4A). Incubating primary hepatocytes with increasing 
concentrations of [3H]TRLs revealed a dose-dependent in-
hibition of TRL clearance by apoC-III in the presence but 
not in the absence of apoE (Fig. 4B, C). Human APOE ex-
ists in three isoforms (APOE2, APOE3, and APOE4) with 
different affinity for LDLR and LRP1. APOE4 and APOE3 
having relatively equal affinity for LDLR and LRP1 com-
pared with apoE2, which has impaired LDLR (<2% of 
apoE3 affinity for LDLR) and LRP1 (30% of apoE3 of 
apoE3 affinity for LRP1) binding (11, 38). Hence, we eval-
uated the binding and uptake of [3H]TRLs reconstituted 
with different human APOE isoforms in primary hepato-
cytes isolated from apoC-III ASO-treated Apoe/Ndst1f/f 
Alb-Cre+ mice. Reconstitution of apoC-III-depleted and 
apoC-III-enriched TRLs with human recombinant apoE 
isoforms was detected as a 35 kDa band (supplemental Fig. 
S3). Murine [3H]TRLs bearing human recombinant 
APOE3 showed improved binding and uptake when apoC-
III was depleted (Fig. 4D). The addition of APOE4 resulted 
in a 1.5-fold increase in uptake of apoC-III-depleted TRLs 
compared with the apoC-III-enriched TRLs (Fig. 4D). In 
contrast, apoC-III did not affect binding and uptake of 
Fig. 1. Targeting ApoC3 with ASOs in chow-fed Apoe/Ndst1f/fAlb-Cre+ mice. A: Apoe/Ndst1f/fAlb-Cre+ mice were administered once weekly 
with apoC-III ASO or control (Ctrl) ASO (50 mg/kg bodyweight) for a period of 8 weeks. Fasting plasma TG levels were measured at the 
indicated time points. B: ApoC-III ASO-mediated relative change of plasma TG levels compared with control ASO. C: Pooled plasma samples 
after 4 weeks of ASO treatment were analyzed by size-exclusion FPLC, and TGs in each fraction were measured. Fasting plasma cholesterol 
levels after apoC-III ASO treatment (D) and relative change in cholesterol compared with control ASO (E). F: FPLC analysis of pooled 
plasma samples after 4 weeks of ASO treatment followed by cholesterol determination in each fraction. G: VLDLs were isolated by ultracen-
trifugation and pooled VLDL samples (5 g of protein per lane) were analyzed by Western blotting with antibodies against apoB, apoC-III, 
and apoE. Hepatic TG (H) and cholesterol (I) levels as well as relative body weight gain (J) were measured (n = 14–17 per group, values 
represent mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001).
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[3H]TRLs reconstituted with the APOE2 isoform (Fig. 4D) 
(11, 39). The results show that apoC-III can only inhibit 
hepatic TRL clearance in the presence of APOE isoforms 
that can functionally bind LDLR and LRP1.
ApoC-III affects FA partitioning to liver and adipose tissue 
in apoE-deficient mice
Initially, apoC-III was shown to be an inhibitor of LPL activ-
ity (40, 41). As we did not find any alterations in hepatic TRL 
clearance and VLDL production, we tested the possibility 
that apoC-III primarily affects LPL activity when apoE ex-
pression is absent by injecting reconstituted Liposyn TRL 
particles radiolabeled with [3H]triolein into Apoe/Ndst1f/f 
Alb-Cre+ mice. Five minutes after intravenous injection of 
[3H]triolein Liposyn TRLs, we analyzed tissue distribution of 
TRL-derived FAs. In Apoe/Ndst1f/fAlb-Cre+ mice, apoC-III 
ASO treatment was associated with a significant 2.8-fold and 
2.3-fold increase in radiolabeled FA partitioning to the liver 
and gWAT, respectively (Fig. 5A). Plasma [3H]triolein levels 
trended lower in the apoC-III ASO-treated mice (supplemen-
tal Fig. S4). ApoC-III ASO treatment did not affect FA distri-
bution to subcutaneous WAT, kidney, spleen, and oxidative 
tissues, such as heart, BAT, and skeletal muscle. The apoC-III 
ASO treatment did not affect tissue weights (Fig. 5B). In a 
parallel experiment, we injected BSA-associated [3H]palmitic 
acid (16:0) intravenously and harvested organs 5 min later. 
ApoC-III ASO-treated Apoe/Ndst1f/fAlb-Cre+ mice showed 
increased [3H]palmitic acid uptake into the liver (Fig. 5C), 
while other tissues, including gWAT, showed a similar FA up-
take compared with control ASO treatment (Fig. 5C). In 
agreement with the in vivo data, primary hepatocytes isolated 
from Apoe/Ndst1f/fAlb-Cre+ mice treated with apoC-III ASO 
showed a significant increase in [14C]oleic acid uptake in a 
time-dependent manner compared with control ASO-treated 
mice (Fig. 5D). Taken together, the results suggest that the 
metabolic fate of FA is altered by apoC-III ASO knockdown. 
Fig. 2. ApoC-III ASO decreases plasma TGs in Apoe/Ndst1f/fAlb-Cre+ mice on a WD. A: ApoC-III ASO or control (Ctrl) ASO (50 mg/kg 
bodyweight) was administered to Apoe/Ndst1f/fAlb-Cre+ mice fed a WD for 8 weeks, and fasting plasma TG values were measured after 2, 4, 
and 8 weeks. B: The relative change in plasma TGs upon apoC-III ASO compared with control ASO. C: Size-exclusion FPLC analysis of 
pooled plasma samples to determine TGs in CR/VLDL, IDL/LDL, and HDL fraction. Measurement of fasting plasma cholesterol levels after 
apoC-III administration (D) and relative change in cholesterol compared with control ASO (E). F: Pooled plasma samples were analyzed by 
FPLC and cholesterol was measured in each fraction. G: Western blot detection of apoB, apoC-III, and apoE in pooled VLDL samples (5 g 
of protein per lane). Hepatic TG (H) and cholesterol (I) levels as well as relative body weight gain (J) were measured (n = 13, values repre-
sent mean ± SEM; *P < 0.05, **P < 0.01).
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RNA sequencing on liver samples isolated from Apoe/Ndst1f/f 
Alb-Cre+ mice revealed minimal differences in hepatic gene 
expression. Compared with control ASO treatment, only 11 
genes were upregulated >1.5-fold and 17 genes downregu-
lated >1.5-fold, taking adjusted P-values <0.05 (Fig. 6A, B). 
No differences in expression of genes involved in de novo li-
pogenesis (Fig. 6C), FA receptors, and transporter proteins 
(Fig. 6D) were observed. Similarly, intracellular processing 
and utilization of FAs in energy metabolism in primary hepa-
tocytes isolated from Apoe/Ndst1f/fAlb-Cre+ mice treated 
with control or apoC-III ASO were unaltered, notwithstand-
ing increased FA uptake upon apoC-III ASO administration 
(Fig. 6E, F). Taken together, the results suggest that apoC-III 
ASO treatment increased FA uptake into gWAT and liver in 
Apoe/Ndst1f/fAlb-Cre+ mice.
ApoC-III inhibits LPL activity in adipose tissue from  
apoE-deficient mice
The increased distribution of TRL-derived FA to liver and 
gWAT in apoC-III-treated Apoe/Ndst1f/fAlb-Cre+ mice 
suggests increased LPL activity. To test this hypothesis, 
Apoe/Ndst1f/fAlb-Cre+ mice treated with control or apoC-
III ASO were intravenously injected with heparin to release 
LPL from endothelial cell surfaces 3 h after an oral gavage 
of corn oil to mimic the postprandial state (Fig. 7A). Ini-
tial postprandial TG levels (t = 0 min) were decreased in 
Apoe/Ndst1f/fAlb-Cre+ mice treated with apoC-III ASO 
compared with control ASO as expected. Heparin-induced 
LPL release lowered plasma TG levels to a similar level in 
both groups, suggesting adequate lipase activity. Unlike pre-
vious observations in apoC-III knockout and apoC-III 
transgenic mouse models, we did not observe an increase 
in pre- and post-heparin plasma lipase activity (data not 
shown) and plasma LPL activity and HL activity when using 
plasma from apoC-III ASO-treated mice compared with 
plasma from control ASO-treated mice (Fig. 7B). Fasting 
NEFA levels did not change, indicating lack of an effect on 
FA release by adipocytes (Fig. 7C). Heparin treatment is 
valuable to estimate the total amount of LPL that is attached 
to capillary walls. However, this measure does not account 
Fig. 3. ApoC-III ASO treatment does not affect hepatic VLDL production and TRL clearance in Apoe/Ndst1f/fAlb-Cre+ mice. 
A: Apoe/Ndst1f/fAlb-Cre+ mice were on apoC-III ASO or control (Ctrl) ASO for 4 weeks. Fasted mice (5 h) were given a 250 l bolus of corn 
oil by oral gavage to measure fat tolerance. Postprandial TG levels were measured 0, 1, 2, and 3 h after gavage (n = 3 per group). B: Hepatic 
VLDL production was determined after intravenous injection of Tyloxapol (0.5 mg/g bodyweight) to block lipase activity. TRL uptake and 
plasma TG levels were measured at the indicated time points (n = 3–5 per group). C: Intestinal lipid absorption was analyzed by intravenous 
injection of Tyloxapol followed by oral gavage of corn oil (250 l). Plasma TG levels were measured at the indicated time points (n = 3). 
D: Hepatic TRL clearance was analyzed by retinyl ester excursion. [3H]retinol (5 Ci) in 250 l corn oil was orally gavaged and the remaining 
counts in the plasma were determined by liquid scintillation counting after 2, 4, 6, and 8 h (n = 3). E: Schematic overview of [3H]TRL clear-
ance experiments in vivo. F: Isolated [3H]TRLs enriched (control ASO) or depleted (apoC-III ASO) in apoC-III were injected intravenously 
into Apoe/Ndst1f/fAlb-Cre+ mice on apoC-III ASO (n = 2). Clearance of [3H]TRLs was assessed by measuring the counts remaining in the 
plasma relative to the counts recovered 1 min after injection (values represent mean ± SEM; *P < 0.05, **P < 0.01).
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for the complex regulation of LPL activity that may be con-
ducted by other factors like apoC-I, apoC-II, ANGPTL3, 
ANGPTL4, and ANGPTL8 (42, 43). These are not necessarily 
tissue specific or dependent on LPL being attached to the 
capillary walls, but their impact is not measured in the in 
vitro LPL activity assay. Given the increased FA distribution 
to gWAT and liver, we tested tissue-specific LPL activity un-
der fasting and feeding conditions in liver, gWAT, and BAT 
(Fig. 7D–F) as described previously (31). Under fasting con-
ditions, no differences in lipase activity between apoC-III-
treated versus control ASO-treated Apoe/Ndst1f/fAlb-Cre+ 
mice were observed in all organs tested. In the fed state, 
significantly higher lipase activity and LPL protein levels 
were observed in gWAT compared with fasting conditions 
in both treatment groups (Fig. 7F). More importantly, 
apoC-III ASO treatment significantly increased LPL activity 
in gWAT isolated from fed mice by 34.5 ± 16.9% compared 
with the control ASO group (Fig. 7F, P = 0.049), while LPL 
protein expression in gWAT was similar between apoC-III- 
and control ASO-treated Apoe/Ndst1f/fAlb-Cre+ mice (Fig. 
7I). In contrast, no differences in total heparin releasable 
lipase activity and LPL levels were detected in liver and BAT 
from fed mice (Fig. 7D, E, G, H).
We next isolated TRLs via ultracentrifugation ( < 1.006) 
to test whether the increased tissue LPL activity was associ-
ated with altered TRL composition and size upon apoC-III 
ASO treatment. In agreement with increased LPL activity, 
TRLs from apoC-III ASO-treated Apoe/Ndst1f/fAlb-Cre+ 
mice on chow diet showed a significant 63% reduction in 
TG levels (Table 1, P = 0.008). In contrast, total cholesterol 
levels were significantly increased (P = 0.048) as a result of 
a 1.4-fold increase in cholesterol ester (CE) content. Con-
sequently, the TG to CE ratio was significantly reduced in 
TRLs from Apoe/Ndst1f/fAlb-Cre+ mice after administration 
Fig. 4. ApoC-III inhibition of TRL clearance requires 
apoE. A–D: Primary hepatocytes were isolated from 
Apoe/Ndst1f/fAlb-Cre+ mice and binding (4°C) and up-
take (37°C) of [3H]retinol-labeled apoC-III-enriched 
and apoC-III-deficient TRL particles were analyzed. A: 
Binding of [3H]TRLs (100 g/ml) enriched or defi-
cient in apoC-III was determined after incubation in pri-
mary hepatocytes in the absence or presence of apoE at 
4°C for 1 h. Binding and uptake was assessed after incu-
bation of [3H]retinol-labeled TRLs at 37°C for 4 h in a 
dose-dependent manner (10/20/50/100 g/ml) in the 
absence (B) and presence (C) of apoE. D: Reconstituted 
[3H]TRLs (50 g) were evaluated in their binding and 
uptake capacity in primary hepatocytes (n = 3 per condi-
tion in all experiments, values represent mean ± SEM; 
*P < 0.05, **P < 0.01, ***P < 0.001).
Fig. 5. ApoC-III lowering increased FA uptake in 
liver and WAT in Apoe/Ndst1f/fAlb-Cre+ mice. A: 
Apoe/Ndst1f/fAlb-Cre+ mice were fasted for 5 h. After a 
5 min intravenous injection of [3H]triolein-labeled li-
posyn particles (100 l), blood and the indicated tis-
sues were harvested (A) and (B) tissue weights were 
determined (B). [3H]triolein tissue uptake was deter-
mined of the homogenized tissues by liquid scintilla-
tion counting (n = 4–6). C: [3H]palmitic acid uptake 
into various tissues of control (Ctrl) ASO- and apoC-III 
ASO-treated mice was analyzed by retro-orbital injec-
tion of 1 Ci (n = 4–6). D: Primary hepatocytes were 
isolated from mice administered with control ASO or 
apoC-III ASO and binding and uptake of [14C]oleic 
acid was assessed in vitro. Hepatocytes were incubated 
with 0.5 Ci of radiolabeled FAs at 37°C, and incorpo-
ration was measured at the indicated time points (n = 3 
per condition; values represent mean ± SEM; *P < 
0.05, **P < 0.01, ***P < 0.001).
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of apoC-III ASO (Table 1, P = 0.002). The free cholesterol 
and protein content of the TRL particles remained un-
changed and the apoC-III ASO treatment did not affect 
TRL particle size and concentration (Fig. 8). It is likely that 
the overall changes in TRL size and composition are 
too subtle to detect. Similarly, we analyzed TRLs isolated 
from Apoe/Ndst1f/fAlb-Cre+ mice on a WD. We observed 
a very modest reduction in TG content and no alteration 
in the TG to CE ratio in TRLs upon apoC-III ASO treat-
ment, which is in line with the modest plasma TG lowering 
under high-fat diet feeding. The cumulative results alto-
gether suggest that apoC-III knockdown reduces plasma 
TG levels in apoE-deficient mice as a result of increased 
LPL activity.
Volanesorsen reduces plasma TGs in patients with the 
APOE2/E2 allele
Treatment with the human apoC-III ASO, volanesorsen, 
effectively lowers plasma apoC-III and TG levels in normolip-
idemic and hyperlipidemic human patients (29, 44, 45). 
Fig. 6. Transcriptomics and metabolomics of hepatocytes from apoC-III ASO-treated Apoe/Ndst1f/fAlb-Cre+ mice. A: Volcano-plot depict-
ing a differential gene expression derived from RNA-seq analysis of livers isolated from fasted Apoe/Ndst1f/fAlb-Cre+ mice receiving apoC-III 
ASO or control (Ctrl) ASO for 8 weeks. Genes that were significantly (adjusted P < 0.05) up- or downregulated upon apoC-III ASO are high-
lighted (excluding Apoc3). B: A heat map showing differentially expressed protein-coding genes with adjusted P-value <0.05 upon apoC-III 
ASO (left panel, n = 5) compared with control ASO (right panel, n = 4). Heat maps of genes involved in de novo lipogenesis (C) and FA 
transport (D). E: ApoC-III ASO or control ASO were administered to Apoe/Ndst1f/fAlb-Cre+ mice and primary hepatocytes were isolated and 
incubated with 20 M U-[13C16]palmitic acid tracer for 1 h and 4 h at 37°C for cellular FA metabolism analysis. After lipid extraction and GC/
MS, enrichment of FA from U-[13C16]palmitic acid tracer and total FA composition were determined. F: Total percentage of C16:0 is shown. 
G: Enrichment of U-[13C16]palmitic acid tracer in metabolites of the TCA cycle (n = 3–4 per condition, values represent mean ± SEM; *P < 
0.05, **P < 0.01, ***P < 0.001).
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However, the impact of the APOE isoforms expressed by the 
individuals on the therapeutic efficiency of volanesorsen is 
unclear. Based on our results, we anticipated no significant 
difference in the efficiency of TG lowering mediated by dif-
ferential APOE isoform expression. We therefore examined 
the data of a previously published randomized double-blind 
placebo-controlled dose-ranging phase 2 study of the effects 
of volanesorsen in patients with hypertriglyceridemia accord-
ing to the distribution of APOE isoforms among patients 
(21). As described previously, a total of 57 patients were 
treated with volanesorsen monotherapy (41 received volane-
sorsen and 16 received placebo), and 28 patients were treated 
with volanesorsen in combination to established fibrate ther-
apy (20 received volanesorsen and 8 received placebo) for 85 
days. APOE isoform genotype and follow-up data were avail-
able for 80 patients and the impact of volanesorsen therapy is 
shown by all genotypes in supplemental Tables S3–S7. In 
general, there was no impact of APOE genotype on the 
Fig. 7. ApoC-III inhibits lipase activity in WAT from Apoe/Ndst1f/fAlb-Cre+ mice. A: Plasma TG levels were measured 3 h after an oral corn 
oil gavage (250 l) before and 10 min after an intravenous heparin injection (50 U per mouse) (n = 3). B: Lipoprotein and HL activities were 
analyzed in post-heparin plasma in mice administered with control (Ctrl) ASO or apoC-III ASO (n = 5–6). C: Fasting NEFA values in mice 
treated with ASOs for 4 weeks (n = 6–8). D–F: Lipase activity was determined in liver (D), BAT (E), and gWAT (F) isolated from fasted (5 h) 
or fed Apoe/Ndst1f/fAlb-Cre+ mice (n = 4–6). Detection of LPL in liver (25 g) (G), BAT (20 g) (H), and gWAT (20 g) (I) by Western 
blotting. LPL expression was quantified relative to -actin (n = 3 per group, values represent mean ± SEM; *P < 0.05, **P < 0.01).
TABLE 1. ApoC-III ASO decreases the TG amount of TRL particles lacking apoE
Chow Diet WD
Control ASO ApoC-III ASO Control ASO ApoC-III ASO
TGs (mol/mg protein) 7.22 ± 1.33 2.68 ± 0.31a 7.24 ± 0.55 5.52 ± 0.23b
Cholesterol (mol/mg protein) 1.48 ± 0.16 1.98 ± 0.15b 3.55 ± 0.19 3.94 ± 0.19
Free cholesterol (mol/mg protein) 0.96 ± 0.13 1.09 ± 0.06 1.87 ± 0.14 2.38 ± 0.13b
Cholesteryl ester (mol/mg protein) 0.29 ± 0.06 0.49 ± 0.06b 0.93 ± 0.04 0.87 ± 0.06
TG/CE 34.2 ± 10.1 6.17 ± 1.20b 7.86 ± 0.63 6.57 ± 0.64
TRLs were isolated from Apoe/Ndst1f/fAlb-Cre+ mice on chow diet (n = 6 per group) of WD (n = 6 per group). 
Values represent mean ± SEM.
aP < 0.01.
bP < 0.05.
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impact of TG lowering mediated by volanesorsen. To illus-
trate these findings, we specifically examined data here of 
patients who were homozygous for APOE2 (E2/E2, n = 7), 
APOE3 (E3/E3, n = 20), and APOE4 (E4/E4, n = 5), respec-
tively (Table 2). The APOE3 homozygous patients received 
placebo (n = 7, with one patient on fibrates) or 100 mg (n = 3, 
no patients on fibrates), 200 mg (n = 7, with four patients on 
fibrates), or 300 mg (n = 3, all patients on fibrates) volane-
sorsen, which significantly reduced APOC-III levels (Fig. 9A). 
Plasma TG levels decreased by 72.8 ± 14.3%, 56.3 ± 14.7%, 
and 61.0 ± 14.0% for the 100, 200, and 300 mg doses, respec-
tively, compared with an 8.7 ± 32.2% increase in the placebo 
group (Fig. 9B). APOE4 homozygote patients received 300 
mg volanesorsen (n = 4) or placebo (n = 1) (with or without 
fibrates). Volanesorsen treatment reduced plasma APOC-III 
and TG levels by 78.6 ± 8.5% and 73.9 ± 6.4%, respectively, 
compared with only 16.2% and 17.6% in the placebo group 
(Fig. 9A, B). Similarly, all APOE2 homozygote patients re-
ceived either placebo (n = 4) or 300 mg volanesorsen (n = 3) 
with or without fibrates. After 85 days of weekly treatment, 
plasma APOC-III and TG levels dropped by 81.6 ± 6.4% and 
73.9 ± 12.7%, respectively, from baseline in the volanesorsen 
cohort, and increased by 7.1 ± 20.0% and decreased by 0.8 ± 
30.6%, respectively, in the placebo group (Fig. 9A, B). Re-
markably, volanesorsen also reduced plasma non-HDL cho-
lesterol (HDL-C) levels by 63.7 ± 7.0% in APOE2 homozygous 
patients (Fig. 9C) but not in APOE3 and APOE4 homozygous 
patients. Overall HDL-C levels increased by 42–60% in this 
cohort of patients administered volanesorsen, whereas HDL-C 
(4.4 ± 20.0%) was unaltered in the placebo groups (Table 2). 
We conclude that volanesorsen lowers plasma TG and in-
creases HDL-C levels in a human hypertriglyceridemia pa-
tient cohort independent of the APOE genotype.
DISCUSSION
Our results present a novel model in which apoE deter-
mines the metabolic impact of apoC-III in TG metabolism 
by shifting apoC-III’s action from attenuating hepatic TRL 
clearance to LPL inhibition (Fig. 10). This is supported by 
our observations that lowering of apoC-III levels using 
ASOs in the absence of apoE did not improve TRL clear-
ance, yet significantly decreased plasma TG levels in vivo. 
This model is in agreement with previous studies in hu-
mans (10) and in compound deficient Apoc3/Apoe/ 
mice (25). Further, we show that apoC-III ASO-associated 
TG lowering in the absence of apoE is a result of increased 
lipase activity and not increased amounts of LPL on capil-
laries, as estimated from LPL activity in post-heparin 
plasma. This was not a generalized improvement in lipase 
activity in all LPL-target tissues, as suggested before, as we 
observed a localized improvement of LPL activity in WAT 
with subsequent augmented FA uptake into WAT and spill-
over of FAs into the liver.
Our data also conclusively demonstrate that apoC-III 
prevents hepatic TRL clearance via LDLR and LRP1 in an 
apoE-dependent fashion. First, ASO-mediated apoC-III 
reduction does not improve hepatic TRL clearance in 
Apoe/Ndst1f/fAlb-Cre+ mice, while it does improve TRL 
clearance in Ndst1f/fAlb-Cre+ mice (5). Finally, apoE-deficient 
[3H]retinol-radiolabeled apoC-III-depleted and apoC-III-
enriched TRLs were internalized by primary hepatocytes at 
the same rate. Reconstitution with apoE reversed this inhi-
bition and significantly improved hepatocyte-associated 
binding and uptake of apoC-III-depleted over apoC-III-en-
riched TRLs. Hence, we hypothesize that apoC-III prevents 
TRL clearance via LDLR and LRP1 by modulating apoE 
binding, but without affecting SDC1 interaction with apoE 
on TRLs. We conclude the latter from our previous obser-
vation that apoC-III did not affect TRL binding and uptake 
in compound LDLR- and LRP1-deficient mice, which ex-
clusively express hepatic SDC1 to clear TRLs (5).
It remains unclear exactly how apoC-III hinders apoE-
mediated TRL clearance via LDLR/LRP1 and not SDC1. 
Multiple mechanisms have been proposed, including di-
rect inhibition by apoC-III of apoE-mediated TRL clear-
ance via LDLR and LRP1 as well as competition between 
Fig. 8. ApoC-III inhibition does not affect the size 
distribution of lipoprotein subclasses. Plasma samples 
of fasted (A) and fed (Β) Apoe/Ndst1f/fAlb-Cre+ mice 
on a chow diet administered with apoC-III ASO or 
control (Ctrl) ASO over 8 weeks were collected. Con-
centrations of plasma lipoprotein subclasses were mea-
sured by particle-size intervals from HDL to VLDL 
using ion mobility. The data represent HDL subclasses 
and intermediates, and show LDL, IDL, and VLDL 
subclasses (n = 3 pooled samples, three samples per 
pool, values represent mean ± SEM).
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apoE and apoC-III for space on TRLs (13, 14, 22–24). Our 
observations suggest that the latter model is improbable, as 
apoE levels on TRLs after reconstitution were not affected 
by the presence or absence of apoC-III. However, previous 
studies reported displacement of apoE from VLDL parti-
cles when apoC-III was overexpressed or added exoge-
nously (5, 13, 22–24, 46). Also, TRL binding and uptake 
after reconstitution with human APOE2 isoforms was unaf-
fected by the presence or absence of apoC-III, providing 
further support that apoC-III-mediated inhibition of TRL 
clearance is not a result of apoE displacement. In such a 
displacement model, one would also expect to affect SDC1-
mediated TRL clearance (9), which we never observed. A 
mechanism where apoC-III inhibits apoE-mediated TRL 
clearance independent of the apoE content on TRLs is 
therefore more likely. Possibilities include the concept that 
apoC-III inhibits TRL clearance by masking apoE and pre-
venting or inducing a conformational change in apoE re-
quired or incompatible for efficient LDLR interactions 
(47, 48). Yet, such a conformation change would not affect 
apoE binding to SDC1 (5, 9).
The apoC-III lowering-induced reduction of plasma TGs 
in Apoe/Ndst1f/fAlb-Cre+ mice was not caused by altered 
VLDL production or intestinal lipid absorption (5, 25, 29, 
49–52). Our observation might imply that the reported in-
crease in lipid absorption observed in Apoc3/Apoe/ 
mice is a result of the loss of intestinal apoC-III expression 
and not related to its expression in the liver (25, 53). As 
neither of the previous metabolic pathways were affected, 
we postulated that increased lipase activity lowered TGs 
and increased FA uptake in Apoe/Ndst1f/fAlb-Cre+ mice 
treated with apoC-III ASO. Although our recent studies in 
mice did not find evidence that apoC-III modulates LPL 
activity (5), apoC-III has historically been established as an 
inhibitor of LPL (25, 40, 54). Jong et al. (25) reported that 
reduced plasma TGs in Apoc3/Apoe/ mice correlated 
with increased clearance of liposyn emulsion-associated FA 
and not human apoB clearance after injection of human 
VLDL. While this suggested increased LPL activity or ex-
pression, it was never confirmed biochemically nor was it 
clear if this observation was dependent on apoE expression 
(25). Our study significantly advances our understanding 
Fig. 9. Volanesorsen lowers plasma TG levels independent of allelic APOE expression in a hypertriglyceridemia cohort. In a randomized double-
blind placebo-controlled dose-ranging phase 2 study, placebo or volanesorsen (100–300 mg) was administered once weekly to patients with dif-
ferent allelic apoE background. Plasma APOC-III (A), plasma TG levels (B), and plasma non-HDL-C levels (C) were measured at baseline and 
after 85 days of either placebo or volanesorsen treatment in patients homozygous for APOE2 (E2/E2), APOE3 (E3/E3), and APOE4 (E4/E4), 
respectively (E2/E2: placebo n = 4, volanesorsen n = 3; E3/E3: placebo n = 7, volanesorsen 100 mg n = 3, 200 mg n = 7, 300 mg n = 3; E4/E4: 
placebo n = 1, volanesorsen n = 4; values represent mean ± SEM, data are shown for patients on monotherapy combined with fibrates).
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of the impact of apoC-III on lipid metabolism and provides 
a more intricate understanding of how apoC-III can impact 
LPL function. First off, we establish that in the absence of 
apoE, lowering apoC-III augments tissue LPL activity and 
not its expression, as we show that this is not a result of in-
creasing heparin-releasable LPL levels. Second, we provide 
evidence suggesting that apoC-III enhances WAT LPL ac-
tivity with ensuing increased free FA uptake in gWAT and 
liver. Interestingly, apoC-III ASO treatment was able to in-
crease gWAT LPL activity beyond levels in tissue normally 
targeted by LPL upon fasting, such as skeletal muscle and 
heart. We do want to point out that, of course, other factors 
could affect LPL activity and LPL protein levels in tissue 
when measured in the presence of heparin. Finally, the use 
of human TRLs is a poor model for studying hepatic TRL 
clearance in mice, as human apoB-TRLs have a very weak 
affinity for murine LDLR. This makes apoB-clearance dif-
ficult to interpret in the study by Jong et al. (25). By using 
murine core [3H]retinol-labeled murine TRLs, we were 
able to more elegantly study the impact of apoC-III on TRL 
clearance in the absence of apoE both in vivo and in vitro. 
Moreover, our apoE in vitro and in vivo complementation 
studies clearly establish the need for apoE in order for 
apoC-III to affect TRL clearance. When comparing the cur-
rent observation in Apoe/Ndst1f/fAlb-Cre+ mice to our pre-
vious data obtained in an LPL-deficient models (5), it is 
interesting to note that apoC-III ASO treatment increased 
both TRL clearance and LPL activity, respectively, in these 
models, resulting in a relative similar capacity to reduce 
plasma TG levels.
Increased LPL activity in gWAT and elevated rates of FA 
uptake into liver, as shown in vivo by both uptake of [3H]
TABLE 2. Combined data of lipid analysis of an APOE cohort administered with placebo or volanesorsen (Ionis 304801) as a monotherapy or  
add-on to fibrates
APOE Isoform Treatment
Parameter
APOC-III (mg/dl) TGs (mg/dl) HDL-C (mg/dl) Non-HDL-C (mg/dl)
E2/E2 Placebo (n = 4) Pre 16.7 ± 5.9 409.5 ± 233.5 37.8 ± 11.1 155.5 ± 64.6
Post 17.3 ± 5.1 370.1 ± 192.3 41.5 ± 9.9 150.4 ± 44.4
Change 7.1 ± 20.0% 0.8 ± 30.6% 13.0 ± 27.1% 1.7 ± 18.9%
Volanesorsen 300 mg (n = 3) Pre 18.9 ± 7.0 538.3 ± 369.5 42.3 ± 12.7 222.7 ± 77.4
Post 3.2 ± 0.7 109.3 ± 15.9 67.0 ± 21.0 77.3 ± 10.7
Change 81.6 ± 6.4% 73.9 ± 12.7% 59.6 ± 21.2% 63.7 ± 7.0%
E3/E3 Placebo (n = 7) Pre 18.8 ± 7.3 379.6 ± 160.3 34.0 ± 5.8 213.6 ± 55.9
Post 18.3 ± 5.3 384.9 ± 138.6 35.5 ± 9.0 198.4 ± 20.4
Change 4.9 ± 32.7% 8.7 ± 32.2% 4.4 ± 20.0% 4.3 ± 14.6%
Volanesorsen 100 mg (n = 3) Pre 27.6 ± 0.9 936.2 ± 109.8 26.0 ± 2.0 258.0 ± 19.7
Post 9.9 ± 4.7 249.5 ± 118.5 41.3 ± 15.5 211.8 ± 14.7
Change 64.6 ± 16.2% 72.8 ± 14.3% 60.0 ± 61.1% 17.6 ± 8.2%
Volanesorsen 200 mg (n = 7) Pre 17.6 ± 5.3 406.6 ± 223.7 33.0 ± 4.8 180.6 ± 44.4
Post 6.0 ± 1.9 158.9 ± 57.9 46.8 ± 9.4 150.9 ± 23.6
Change 65.3 ± 10.1% 56.3 ± 14.7% 41.9 ± 18.9% 14.0 ± 15.2%
Volanesorsen 300 mg (n = 3) Pre 15.7 ± 1.8 255.2 ± 17.1 39.7 ± 14.6 165.3 ± 47.0
Post 5.5 ± 2.3 98.0 ± 30.4 61.2 ± 29.3 134.5 ± 19.0
Change 64.0 ± 16.5% 61.0 ± 14.0% 51.1 ± 44.9% 15.5 ± 18.0%
E4/E4 Placebo (n = 1) Pre 25.5 495.0 30.0 316.0
Post 21.4 408.0 31.0 281.0
Change 16.2% 17.6% 3.3% 11.1%
Volanesorsen 300 mg (n = 4) Pre 22.7 ± 5.1 579.9 ± 257.5 26.5 ± 8.4 205.5 ± 21.6
Post 4.7 ± 1.5 147.1 ± 68.5 39.1 ± 11.8 179.9 ± 30.1
Change 78.6 ± 8.5% 73.9 ± 6.4% 48.7 ± 9.5% 12.1 ± 15.9%
Values represent mean ± SD.
Fig. 10. The role of apoC-III on lipoprotein metabo-
lism varies depending on apoE. Schematic representa-
tion of how apoE determines the metabolic fate of 
apoC-III in TG metabolism by shifting apoC-III’s versa-
tile role from attenuating hepatic TRL clearance to 
LPL inhibition.
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triolein-labeled liposyn particles and [3H]palmitic acid and 
in vitro by [14C]oleic acid and gWAT might result in altered 
FA metabolism and energy usage. Recently, an apoC-III 
gain-of-function mutation (Gln38Lys) was associated with 
increased hepatic de novo lipogenesis measured by upregu-
lation of SREBP-1/2, FAS, ACC1, and CD-36, and FA syn-
thesis (52). Another study in rats also showed an association 
between lower apoC-III levels and increased FA oxidation 
and a decrease in plasma TG levels (55). However, RNA se-
quencing and metabolite analysis of livers from apoC-III 
ASO-treated Apoe/Ndst1f/fAlb-Cre+ mice only revealed min-
imal differences compared with control ASO-treated mice. 
No significant changes in genes involved in FA transport 
and de novo lipogenesis were detected. However, one can-
not rule out that apoC-III lowering affects protein levels or 
the transport and interaction of FA with hepatic receptors.
Our proposed metabolic switch model has clinical rele-
vance, as apoC-III ASO administration in a clinical study 
lowered plasma TG levels in hypertriglyceridemia patients 
independent of the expressed APOE isoform. APOE exists in 
three isoforms in humans (APOE2, APOE3, and APOE4) that 
have a different affinity for LDLR and LRP1. The receptor-
binding domain of apoE (residues 135–150) is enriched in 
basic arginine and lysine residues, which interact with acidic 
amino acids of the calcium-binding repeat of LDLR (39, 
56). APOE3 and APOE4 carry an arginine residue at position 
158, which mediates binding to LDLR (11). In contrast, 
APOE2 contains a cysteine residue at this position resulting 
in a conformational change of the receptor-binding do-
main and ultimately defective binding to LDLR (<2% of 
normal LDLR binding activity) and LRP1 (30–50% of nor-
mal LRP1 binding activity) (11, 38). APOE2 homozygosity is 
associated with recessive inheritance and low penetrance of 
type III hyperlipoproteinemia (57). We analyzed the impact 
of APOE genotype in hypertriglyceridemia patients from a 
previous study testing the efficacy of ASO-mediated APOC-
III lowering with volanesorsen in relation to apoE isoforms 
(19, 21, 44, 45). As expected, our retrospective analysis 
shows that volanesorsen reduced plasma TGs in homozy-
gous APOE3 or APOE4 (or a combinations of those isoforms) 
hypertriglyceridemia patients most likely by facilitating TRL 
clearance via LDLR and LRP1 (5). Remarkably, APOC-III 
lowering also strongly reduced plasma TG levels in APOE2 
homozygous patients. These results are in sharp contrast to 
earlier observations from APOE2-knockin mice where com-
pound apoC-III inactivation did not alter total plasma 
TG levels (58). This contradiction with our data in human 
APOE2 homozygous patients suggests that human APOE iso-
forms differentially affect TG metabolism in humans com-
pared with mice. The limited murine APOE2-knockin study 
did not assess the impact of apoC-III deficiency on lipid ab-
sorption, VLDL production, and TRL clearance (58). It is 
possible that the increased intestinal lipid absorption ob-
served in compound deficient Apoc3/Apoe/ mice also 
manifests in APOE2-knockin mice (25). If so, this increased 
absorption could counterbalance any improvement on 
LPL-driven clearance of plasma TGs due to loss of apoC-III 
expression. Because human APOE2 homozygous hypertri-
glyceridemia patients lack the ability to efficiently clear 
TRLs through the LDLR/LRP1 axis, our results suggest that 
volanesorsen can reduce plasma TG levels independent of 
this apoE-driven hepatic TRL clearance pathway. In hu-
mans, genetically reducing plasma APOC-III by only 50% 
led to enhanced conversion of plasma VLDL to LDL and 
lowering of VLDL-TG by 45%, without evidence for en-
hanced hepatic VLDL remnants and LDL removal and 
accumulation (59). Thus, the consequence of lowering of 
APOC-III by >70% by volanesorsen in the E2/E2 homozy-
gotes seems to allow LPL to reduce plasma TGs by approxi-
mately 80%, as noted in our study. Limitations of this 
unique clinical study are the small sample size, especially 
of patients with low-abundant homozygous APOE-isoforms 
(E2 and E4). Despite this restriction, most of the ob-
served plasma TG reductions upon volanesorsen treatment 
were profound and present in all treated patients, accentu-
ating the robustness of our findings.
Altogether, our study shows for the first time that the 
apoE genotype in hypertriglyceridemia patients does not 
negatively affect the efficiency of volanesorsen to lower 
plasma TGs. Further in-depth investigation will be needed 
to address exactly how apoC-III can differentially affect 
apoE-mediated TRL clearance by LDLR/LRP1 and SDC1. 
More importantly, it needs to be determined whether the 
distinctly different TG clearance pathways modulated by 
APOC-III have a differential impact on CVD and longevity, 
which are associated with altered plasma apoC-III levels in 
the human population.
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